Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
NCT00419146, Phase 2, Phase 3, Completed, University Hospital, Aker
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants | ClinicalTrials.gov |
| NCT number | NCT00419146 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 2, Phase 3 | ClinicalTrials.gov |
| Enrollment | 99 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Aker | ClinicalTrials.gov |
| Conditions | Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychotic Disorders | ClinicalTrials.gov |
| Interventions | Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C, Etyl EPA (placebo), Vitamins E+C (placebo) | ClinicalTrials.gov |
| First posted | 2007-01-08 | ClinicalTrials.gov |
| Last updated | 2011-01-04 | ClinicalTrials.gov |
Registered outcomes 43
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Positive and Negative Syndrome Scale (PANSS)- Total | Baseline - 8 weeks - 16 weeks | ClinicalTrials.gov | |
| Secondary | PANSS Subscales Negative, Positive, General Psychopathology | Weeks 0, 8, 16 | ClinicalTrials.gov | |
| Secondary | GLOBAL ASSESSMENT OF FUNCTIONING- Split Version (S-GAF) | Weeks 0, 8, 16 | (S-GAF)Symptom Scale (S-GAF)Function Scale | ClinicalTrials.gov |
| Secondary | WONCA-COOP FUNCTIONAL HEALTH ASSESSMENT CHARTS | Weeks 0, 8, 16 | 5 scales | ClinicalTrials.gov |
| Secondary | NIACIN SKIN FLUSH TEST | Weeks 0, 8, 16 | 2 concentrations of niacin | ClinicalTrials.gov |
| Secondary | THE UKU SIDE EFFECT RATING SCALE (USERS) | Weeks 0,4,8,12,16 | 1. Sum of scores 2. Patients with side effects | ClinicalTrials.gov |
| Secondary | SERIOUS ADVERSE EVENTS | Weeks 0,4,8,12,16 | ClinicalTrials.gov | |
| Secondary | CONCOMITANT ANTIPSYCHOTIC MEDICATION | Weeks 0,4,8,12,16 | Defined Daily Doses (ATC/WHO) | ClinicalTrials.gov |
| Secondary | Kimura Recurring Recognition Figures Test | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Hopkins Verbal Learning Test. | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Continuous Performance Test | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Hopkins Verbal Learning Test | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Paced Auditory Serial Addition Test | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Stroop Test | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Digit Span | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | The Letter - Number Task | Weeks 0,16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Semantic and Category Fluency | Weeks 0, 16 | A sub-sample of patients. For logistic reasons, only some study sites could participate. | ClinicalTrials.gov |
| Secondary | Body Mass Index | Weeks 0, 16 | ClinicalTrials.gov | |
| Secondary | Blood pressure - systolic, diastolic | Weeks 0, 16 | ClinicalTrials.gov | |
| Secondary | Heart rate | Weeks 0, 16 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Continuous Performance Test | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Paced Visual Serial Addition Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)